Creo Medical Group (LON:CREO) Posts Earnings Results

Creo Medical Group (LON:CREO) announced its earnings results on Wednesday. The company reported GBX (2) earnings per share for the quarter, Digital Look Earnings reports. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%.

Creo Medical Group Price Performance

LON CREO traded down GBX 1.48 during mid-day trading on Wednesday, hitting GBX 10.40. The stock had a trading volume of 7,994,368 shares, compared to its average volume of 783,030. The firm’s 50 day moving average is GBX 12.77 and its 200 day moving average is GBX 12.87. The company has a debt-to-equity ratio of 8.20, a current ratio of 3.22 and a quick ratio of 2.19. The stock has a market capitalization of £50.52 million, a price-to-earnings ratio of 10.40 and a beta of 1.56. Creo Medical Group has a twelve month low of GBX 9.52 and a twelve month high of GBX 18.50.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group reissued a “house stock” rating and issued a GBX 40 price target on shares of Creo Medical Group in a report on Thursday, July 23rd.

About Creo Medical Group

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.